EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

類似資料

• EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
  著者:: Tzogani, Kyriaki, 等
  出版事項: (2020)
• Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T‐Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease
  著者:: Ali, Sahra, 等
  出版事項: (2019)
• EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors
  著者:: Karres, Dominik, 等
  出版事項: (2020)
• EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma
  著者:: Michaleas, Sotirios, 等
  出版事項: (2020)
• The European Medicines Agency Review of Bosutinib for the Treatment of Adult Patients With Chronic Myelogenous Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
  著者:: Hanaizi, Zahra, 等
  出版事項: (2014)